CYTOKINES AND OTHER INFLAMMATORY MEDIATORS OF AXONAL INJURY
Lists
Only you see this
Abstract
The infiltration of peripheral blood T-lympho- cytes into the central nervous system (CNS) is observed to some degree in most patients with active multiple sclerosis (MS) lesions. Several lines of evidence support a role of T-cells in the develop- ment of MS lesions. T-lymphocytes produce several soluble mediators that contribute directly or indi- rectly to neuronal degeneration. However, many mediators released by T-lymphocytes or other immune cells (eg, macrophages) have both benefi- cial and harmful effects in the CNS. Several in vitro methods have been developed to quantify the cel- lular and molecular mechanisms underlying human neuronal injury. Measures of neuronal death, neu- rite retraction, oxidative stress, or mitochondrial membrane potential may provide new tools to eval- uate potential neuroprotective therapies for MS and other CNS disorders. (Adv Stud Med. 2004;4(4B):S322-S326) mediators produced by T-lymphocytes and other immune cells that contribute to neuronal pathology. These studies have described a series of complex interac- tions between inflammatory mediators and their cellular targets, with many of these substances producing both beneficial and harmful effects. These complex interac- tions may make it difficult to significantly improve the course of MS by therapeutic strategies that target only a single mediator or intracellular signaling pathway. Several lines of evidence suggest that T-cells are important in the pathogenesis of MS. As described by Dr Raine, T-cells are present at the margins of active MS lesions. The risk of developing MS has been associated with specific class II major histocompatibility complex (MHC) molecules suggesting an important role for CD4+ T-cells. Myelin basic protein (MBP)-specific T- cells in peripheral blood display increased rates of somat- ic mutation and memory. Clinical trials examining the modification of immune activity have also provided cir- cumstantial evidence regarding the importance of T-lym- phocytes in MS. In the Altered Peptide Ligand (APL) trial, patients with MS were treated with a peptide designed to partially mimic the encephalitis-producing epitope of MBP with the goal of blocking T-cell respons- es to MBP or shifting T-cell activity to a regulatory pro- file. 2 However, the status of several patients who received the peptide worsened dramatically, with increased num- bers of contrast-enhancing lesions and clinical exacerba- tions. Cross-reactivity was demonstrated between the APL and MBP, as well as the expansion of MBP-reactive T-cells. Instead of APL acting as a weak agonist and dri- ving a TH2 response as intended, the APL signaled T-cell receptors and activated TH1 myelin-reactive cells, which led to a marked increase in the number of active enhanc- ing lesions in some patients. These findings suggest that T-lymphocytes are inti- mately linked to the initial inflammatory demyelina- tion in MS. Recent evidence suggests that T-cells might also mediate direct damage to neurons and axons. It is widely believed that therapies targeting the
BibTeX
@inproceedings{calabresi2004cytokines,
author = {Peter A. Calabresi},
title = {{CYTOKINES AND OTHER INFLAMMATORY MEDIATORS OF AXONAL INJURY}},
booktitle = {Advanced},
year = {2004},
}Loading related content...